$NXTS +34% 🚀 🔹 Momentum ripping as traders start catching onto the Nexentis story 🔹 MitoCareX Bio hit a key R&D milestone, generating a substantially improve

$NXTS +34% 🚀 🔹 Momentum ripping as traders start catching onto the Nexentis story 🔹 MitoCareX Bio hit a key R&D milestone, generating a substantially improved hit molecule on the path toward pre-clinical development 🔹 MITOLINE® platform continues to drive the drug discovery angle, with recent U.…